Myxo ETlogix Ring


	Heart Valve Repair

Carpentier-Edwards Physio II

Carpentier-Edwards Physio Tricuspid

Carpentier-Edwards Physio

Cosgrove-Edwards

Myxo ETlogix

GeoForm

IMR ETlogix

Edwards MC3 Tricuspid

Carpentier-Edwards Classic

Related Products

Request Information

Technical Information

Patient Website

Heart Valve News

Report from NPR

2006 ACC / AHA Guidelines

Heart Valve Education

Myxo ETlogix Ring

Mitral valve repair is the gold standard¹
In patients with an average age of 56 years, mitral valve repair restores the normal survival curve while avoiding the limitations of mechanical valve replacement.

Excess leaflet tissue associated with myxomatous disease
Myxomatous disease is characterized by elongated, thickened leaflets that result in leaflet billowing, annular dilatation, ruptured chords and mitral regurgitation (MR).²

Move instead of remove
The Myxo ETlogix ring moves the posterior leaflet inferiorly thereby reducing the reconstruction required to decrease the posterior leaflet height.³

Mitigate SAM and LVOTO
Extends the posterior leaflet up and away from the left ventricular outflow tract (LVOT) mitigating systolic anterior motion (SAM) and LVOTO with less leaflet reconstruction.³

Designed for ease of use
See cut away view and image of holder

Robust silicone sewing margin designed for effortless needle placement
Polyester velour cloth chosen to ensure smooth suture slide
Specially designed holder simplifies visualization of the restored coaptation line
Rigid titanium core reshapes the annulus to accommodate excess leaflet tissue

References:
1. Braunberger E, et al. Very long-term results (more than 20 years) of valve repair with Carpentier's techniques in nonrheumatic mitral valve insufficiency. Circulation. 2001;104(12 Suppl 1):I8-11.
2. Perier P, et al. Valve repair for mitral regurgitation caused by isolated prolapse of the posterior leaflet. Ann Thorac Surg 1997;64(2):445-50.
3. Maslow AD, et al. Echocardiographic predictors of left ventricular outflow tract obstruction and systolic anterior motion of the mitral valve after mitral valve reconstruction for myxomatous valve disease. J Am C Cardio 1999;34(7):2096-104.

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.


Animation

Implantation Video

Case Presentation

Model

Accessories